The pso Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the pso Hub cannot guarantee the accuracy of translated content. The pso and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB: For educational content and news updates.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View pso content recommended for you
Guselkumab vs fumaric acid esters for plaque psoriasis: Results from POLARIS trial
|
Results from the phase III POLARIS trial, comparing guselkumab (GUS) with fumaric acid esters (FAE) in systemic treatment-naïve patients with moderate-to-severe plaque psoriasis, have been published in British Journal of Dermatology by Thaci et al.1 The trial assessed long-term safety and efficacy of GUS, as well as the durability of responses after stopping GUS treatment.1
|
| Key learnings: |
|
At Week 32, 78% and 90% of patients treated with GUS achieved 75% improvement in Psoriasis Area and Severity Index (PASI 75) and PASI 90, compared with 12% and 24% of FAE-treated patients, respectively. |
|
At Week 56, 91% of GUS-treated patients maintained PASI 90 response vs 50% of FAE-treated patients. PASI 90 response was also achieved by 80% of patients who switched from FAE to GUS at Week 32. |
|
47% of GUS-GUS withdrawal patients and 25% of FAE-GUS withdrawal patients maintained a PASI score ≤5 at Week 100. |
| Incidence of adverse events and treatment discontinuation was lower in both the GUS and switched to GUS groups compared with the FAE group. |
| In this study, GUS demonstrated superior long-term efficacy and safety compared with FAE for systemic treatment-naïve patients, suggesting potential as a preferred first-line systemic therapy. |
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content